Results 121 to 130 of about 591 (191)

First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors. [PDF]

open access: yesOncologist
Gutierrez ME   +10 more
europepmc   +1 more source

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From <i>EGFR</i>-Mutant NSCLC Informs Potential Therapeutic Targets. [PDF]

open access: yesJTO Clin Res Rep
Zhang B   +35 more
europepmc   +1 more source

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies. [PDF]

open access: yesJ Hematol Oncol
Ouyang Q   +27 more
europepmc   +1 more source

Longitudinal Tracking of <i>ALK</i>-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. [PDF]

open access: yesJTO Clin Res Rep
Heeke S   +21 more
europepmc   +1 more source

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve <i>EGFR</i>-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). [PDF]

open access: yesJ Clin Oncol
Le X   +29 more
europepmc   +1 more source

Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer. [PDF]

open access: yesJ Immunother Cancer
Ghiringhelli F   +23 more
europepmc   +1 more source

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial. [PDF]

open access: yesJ Clin Oncol
Marth C   +30 more
europepmc   +1 more source

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. [PDF]

open access: yesCancer Res Commun
Yarchoan M   +19 more
europepmc   +1 more source

Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma. [PDF]

open access: yesJ Clin Oncol
Hamid O   +31 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy